Clincosm LogoSign in Get a demo

EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05703815
Collaborator
(none)
40
Enrollment
1.9
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world.

In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%.

The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management.

Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis.

P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    40 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast and Their Association With the Clinicopathological Prognostic Paremeters
    Anticipated Study Start Date :
    Jan 1, 2023
    Anticipated Primary Completion Date :
    Mar 1, 2023
    Anticipated Study Completion Date :
    Mar 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Diagnosis of breast cancer [two day after staining sections with Immnnohistochemical markers]

      Immunohistochemical expression of EpCAM and P53 in IDC of the breast

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 80 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study.
    1. Complete clinical data.
    Exclusion Criteria:

    1. Patients with recurrence of the primary tumor.

    2. Patients with a history of preoperative chemotherapy and/or radiotherapy.

    3. Insufficient or tiny tissue biopsies

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Sohag University

    Investigators

    • Principal Investigator: Rasha M Abdelkareem, Sohag University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Rasha Mokhtar Abdelkareem, lecturer, Sohag University
    ClinicalTrials.gov Identifier:
    NCT05703815
    Other Study ID Numbers:
    • Soh-Med-23-01-34
    First Posted:
    Jan 30, 2023
    Last Update Posted:
    Jan 31, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Rasha Mokhtar Abdelkareem, lecturer, Sohag University
    EpCAM, P53 , IDC
    Additional relevant MeSH terms:
    Carcinoma, Ductal
    Breast Neoplasms

    Study Results

    No Results Posted as of Jan 31, 2023